Overview
- The Washington Post reported that the Centers for Medicare & Medicaid Services is preparing a pilot that could begin next year.
- Experts quoted describe a narrow design focused on oncology, palliative care and possibly chronic pain, with pharmaceutical‑grade products and tight dosing controls.
- Supporters argue that reimbursing CBD could curb opioid reliance and reduce Medicare spending if it safely relieves pain and chemotherapy side effects.
- Any coverage is expected to start as a limited pilot with strict eligibility and would proceed through CMS processes before any broader rollout.
- The push is being discussed alongside potential federal changes to marijuana policy, including possible reclassification to Schedule III.